Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Balicer, Ran D., Huerta, Michael, Davidovitch, Nadav, Grotto, Itamar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2005
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320484/
https://www.ncbi.nlm.nih.gov/pubmed/16102319
http://dx.doi.org/10.3201/eid1108.041156
_version_ 1782228841472720896
author Balicer, Ran D.
Huerta, Michael
Davidovitch, Nadav
Grotto, Itamar
author_facet Balicer, Ran D.
Huerta, Michael
Davidovitch, Nadav
Grotto, Itamar
author_sort Balicer, Ran D.
collection PubMed
description We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.
format Online
Article
Text
id pubmed-3320484
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-33204842012-04-11 Cost-Benefit of Stockpiling Drugs for Influenza Pandemic Balicer, Ran D. Huerta, Michael Davidovitch, Nadav Grotto, Itamar Emerg Infect Dis Dispatch We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts. Centers for Disease Control and Prevention 2005-08 /pmc/articles/PMC3320484/ /pubmed/16102319 http://dx.doi.org/10.3201/eid1108.041156 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Balicer, Ran D.
Huerta, Michael
Davidovitch, Nadav
Grotto, Itamar
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
title Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
title_full Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
title_fullStr Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
title_full_unstemmed Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
title_short Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
title_sort cost-benefit of stockpiling drugs for influenza pandemic
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320484/
https://www.ncbi.nlm.nih.gov/pubmed/16102319
http://dx.doi.org/10.3201/eid1108.041156
work_keys_str_mv AT balicerrand costbenefitofstockpilingdrugsforinfluenzapandemic
AT huertamichael costbenefitofstockpilingdrugsforinfluenzapandemic
AT davidovitchnadav costbenefitofstockpilingdrugsforinfluenzapandemic
AT grottoitamar costbenefitofstockpilingdrugsforinfluenzapandemic

Ejemplares similares